What Is Medical Cannabis?

Medical cannabis refers to the use of the cannabis plant or its extracts to treat symptoms of illness or other medical conditions. It is not a single product but a broad category encompassing whole-plant cannabis (flower, concentrates, edibles), standardized extracts, and pharmaceutical-grade cannabinoid medications. While the cannabis plant itself is not FDA-approved as a medicine, several cannabis-derived and cannabis-related compounds have received FDA approval, and 38 states plus the District of Columbia have established regulated medical cannabis programs.

If you are reading this page, you are likely considering whether medical cannabis might help with a condition you or someone you care about is dealing with. This guide is designed to give you the information you need to have that conversation — with your healthcare provider, with yourself, or with a family member — grounded in what the research actually shows.

The distinction between medical and recreational cannabis is not about the plant itself — it is about intent, oversight, and how products are selected and used:

• Intent: Medical use is directed at alleviating specific symptoms or conditions, not primarily for enjoyment or relaxation.
• Oversight: Medical patients ideally work with a healthcare provider who can help guide product selection, dosing, monitoring, and integration with other treatments.
• Product selection: Medical use often involves precise dosing, specific cannabinoid ratios (such as high-CBD or balanced THC:CBD), and delivery methods chosen for consistency and duration rather than potency or onset speed.

FDA-Approved Cannabinoid Medications

Four cannabinoid-based medications have received full FDA approval, meaning they have passed rigorous clinical trials demonstrating safety and efficacy:

• Epidiolex (cannabidiol / CBD) — purified, plant-derived CBD approved for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. The strongest regulatory validation in cannabis medicine.
• Marinol / dronabinol (synthetic THC) — approved for chemotherapy-induced nausea and vomiting and for anorexia associated with weight loss in AIDS patients.
• Syndros (dronabinol oral solution) — a liquid formulation of synthetic THC with the same indications as Marinol.
• Cesamet / nabilone (synthetic cannabinoid) — approved for chemotherapy-induced nausea and vomiting that has not responded to other treatments.

Additionally, Sativex (nabiximols), a standardized whole-plant extract containing roughly equal parts THC and CBD, has been approved in more than 30 countries for multiple sclerosis spasticity, though it has not yet received FDA approval in the United States.

State-Legal Medical Cannabis Programs

Beyond FDA-approved medications, 38 states and the District of Columbia have established medical cannabis programs that allow patients with qualifying conditions to legally access cannabis products under state law. These programs operate in a legal gray area — they are legal under state law but technically violate federal law, which still classifies cannabis as a Schedule I substance. In practice, however, the federal government has generally not interfered with state medical cannabis programs.

State programs vary enormously in their qualifying conditions, product availability, patient limits, and costs. Some allow only low-THC products, while others provide access to the full range of cannabis products. Our Medical Programs by State guide provides a detailed breakdown.

The Evidence Spectrum

Not all medical cannabis claims are created equal. Some conditions have decades of clinical trial data behind them. Others rely primarily on patient reports and preclinical research. Understanding where your condition falls on this spectrum is one of the most important steps in making an informed decision.

The Evidence Spectrum

This is the centerpiece of this guide and arguably the most important section on this entire website. Understanding the quality of evidence for your specific condition is the single best thing you can do before making a decision about medical cannabis.

The following categorization is based primarily on the landmark 2017 National Academies of Sciences, Engineering, and Medicine report — the most comprehensive review of cannabis research ever conducted, analyzing over 10,000 scientific abstracts — updated with significant findings published through early 2026, including the 2025 JAMA comprehensive review by Hsu et al. that assessed more than 2,500 studies.

The National Academies report reviewed over 10,000 scientific abstracts and remains the most authoritative assessment of the therapeutic and adverse effects of cannabis. It categorized evidence into tiers based on the quality and consistency of available research.

National Academies of Sciences, Engineering, and Medicine, 2017

Strong Evidence Strong Evidence

Supported by multiple randomized controlled trials, systematic reviews, and/or FDA-approved medications.

• Chemotherapy-induced nausea and vomiting — Two FDA-approved synthetic cannabinoids (dronabinol, nabilone) have demonstrated efficacy in clinical trials. Cannabis-based treatments are most often used when standard anti-emetics are insufficient. Learn more.
• Certain epilepsy syndromes — Epidiolex (purified CBD) reduced seizure frequency by 37–42% in rigorous clinical trials for Dravet syndrome and Lennox-Gastaut syndrome. This represents the gold standard of cannabis medicine evidence. Learn more.
• Chronic neuropathic pain — Multiple systematic reviews have found that cannabinoids provide modest but statistically significant relief for nerve-related pain, including diabetic neuropathy and HIV-associated neuropathy. Learn more.
• Spasticity in multiple sclerosis — Sativex (THC:CBD spray) has been approved in 30+ countries based on clinical trial evidence showing meaningful reduction in patient-reported spasticity. Learn more.

Moderate Evidence Moderate Evidence

Supported by clinical trials and large observational studies, though more research is needed for definitive conclusions.

• Chronic non-neuropathic pain — Evidence is encouraging, particularly for opioid dose reduction (a 2025 JAMA study found a 22% reduction in opioid doses among medical cannabis patients), but results are less consistent than for neuropathic pain. Learn more.
• Sleep disorders (short-term) — THC may reduce the time it takes to fall asleep and increase total sleep time in the short term, but tolerance develops with regular use, and long-term effects on sleep architecture are not well understood. Learn more.
• PTSD symptoms — A 2025 systematic review found 70% of the highest-quality studies reported positive improvement in PTSD symptoms. Nabilone has shown particular promise for treatment-resistant nightmares. Learn more.
• Appetite stimulation in HIV/AIDS — Dronabinol is FDA-approved for AIDS-related anorexia and wasting. Whole-plant cannabis is also widely reported to improve appetite, though head-to-head comparisons with modern antiretroviral-era patients are limited. Learn more.

Limited Evidence Emerging / Mixed Evidence

Limited clinical trials and mostly observational data. Results are inconsistent or complicated by dose-dependent effects.

• Anxiety — This is dose-dependent in ways that matter enormously: low-dose CBD and low-dose THC may reduce anxiety, while higher THC doses can significantly worsen it. The biphasic effect makes this one of the trickiest conditions to treat with cannabis. Learn more.
• Depression — Observational data suggests some patients experience mood improvement, but there is a lack of controlled clinical trials. Chronic heavy use is associated with worse depressive outcomes. Learn more.
• Inflammatory bowel disease — Preclinical evidence for anti-inflammatory effects is strong, and patient surveys report symptom improvement, but rigorous clinical trials have produced inconsistent results. Learn more.
• Fibromyalgia — Several observational studies report symptom improvement, particularly for pain, sleep, and anxiety. However, there is a shortage of randomized controlled trials. Learn more.
• Migraines — A growing body of retrospective and survey-based evidence suggests cannabis may reduce migraine frequency and intensity, but controlled trials are largely absent. Learn more.

Limited Evidence Insufficient Evidence

Primarily preclinical data (lab or animal studies) or very limited human data. These areas need substantially more research before drawing conclusions.

• Cancer treatment (distinct from symptom management) — While cannabinoids have shown anti-tumor effects in cell cultures and animal models, there is no reliable human clinical trial evidence that cannabis treats cancer itself. The evidence for managing cancer-related symptoms (nausea, pain, appetite loss) is much stronger.
• Alzheimer's disease and dementia — Preclinical research has explored anti-inflammatory and neuroprotective properties of cannabinoids, but human evidence is extremely limited and inconclusive.
• Autism spectrum disorder — Early observational studies, particularly from Israel, suggest possible benefits for behavioral symptoms, but controlled clinical trials are only beginning.
• Glaucoma — While cannabis can temporarily reduce intraocular pressure, the effect lasts only 3 to 4 hours, making it impractical as a treatment when compared to modern eye drops that work around the clock. Most ophthalmologists do not recommend it.

Who Should Consider Medical Cannabis

Medical cannabis is not for everyone, and it is not a first-line treatment for most conditions. The patients who tend to have the best outcomes are those who approach it thoughtfully, with realistic expectations, and as part of a broader health strategy. Medical cannabis is most appropriately considered when:

• You have tried conventional treatments without adequate relief. If standard medications, therapies, and lifestyle changes have not sufficiently improved your symptoms, medical cannabis may be worth discussing with your provider. This is especially true for conditions like chronic pain, where patients may have cycled through multiple treatments with partial or inadequate results.
• You are experiencing significant side effects from current medications. Some patients find that cannabis allows them to reduce reliance on medications with burdensome side effects — particularly opioids, benzodiazepines, and sleep medications — though this must always be done under medical supervision. Never stop or reduce prescription medications on your own.
• You have a qualifying condition in your state. Each state's medical cannabis program has an approved list of conditions. If your condition qualifies, the legal pathway is clearer and the protections are greater. Even in recreational states, a medical card provides advantages.
• You are willing to work with a healthcare provider. The best outcomes come from patients who use cannabis as part of a monitored treatment plan, not as a self-prescribed alternative to medical care. This means honest conversations about what is and is not working.
• You can afford the out-of-pocket costs. Health insurance does not cover medical cannabis due to its federal scheduling. Monthly costs typically range from $100 to $300, plus the cost of a medical card. This is a real barrier for many patients and should be factored into your decision.
• You are comfortable with a degree of uncertainty. For many conditions, the evidence is promising but not definitive. Medical cannabis may require trial and error with products, doses, and timing before finding what works for you — and for some patients, it may not work at all.

Who Should Not Use Cannabis

Certain groups face elevated risks from cannabis use. If any of the following apply to you, medical cannabis is either inadvisable or requires extreme caution and close medical supervision:

• Pregnant or breastfeeding individuals — THC crosses the placenta and is present in breast milk. No amount of cannabis has been established as safe during pregnancy or breastfeeding. Learn more.
• People under 25 — The brain continues developing into the mid-twenties. Regular cannabis use during this period is associated with measurable effects on cognitive function, memory, and in vulnerable individuals, increased risk of psychotic disorders.
• Personal or family history of psychosis or schizophrenia — Cannabis, particularly high-THC products, can trigger or worsen psychotic episodes in predisposed individuals. This is one of the most well-established risks in cannabis research. Learn more.
• Certain cardiovascular conditions — Cannabis can increase heart rate and has been associated with elevated cardiovascular risks, particularly in those with existing heart disease or risk factors. Learn more.
• Those on medications with serious CYP450 interactions — Cannabis is metabolized by and inhibits several liver enzymes in the CYP450 system, which can alter the blood levels of many common medications including blood thinners, immunosuppressants, certain antidepressants, and anti-seizure drugs. Learn more.

For the full list of contraindications and risk factors, see our comprehensive Who Should Not Use Cannabis page.

How to Get Started with Medical Cannabis

If you have weighed the evidence and believe medical cannabis may be appropriate for your situation, here is a practical, step-by-step roadmap. The process may feel overwhelming at first, particularly navigating state regulations and choosing products, but it becomes manageable once you understand the key steps.

The entire process from initial doctor conversation to first dispensary visit typically takes 2 to 6 weeks, depending on your state's processing time and appointment availability.

Step 1: Talk to Your Doctor

This is the single most important step. A healthcare provider who knows your medical history, current medications, and overall health picture can help you evaluate whether cannabis is appropriate and safe for you. Be honest about your interest and your reasons — most providers appreciate transparency, even if they have reservations about cannabis.

If your current doctor is not knowledgeable about cannabis or is unwilling to engage, the Society of Cannabis Clinicians maintains a directory of trained providers, and Leaf411 provides free access to cannabis-trained registered nurses. See our Talking to Your Doctor page for conversation starters and what to expect.

Step 2: Check Your State's Qualifying Conditions

Every state medical cannabis program has a specific list of qualifying conditions. Some states are strict (a short list of serious conditions like cancer, epilepsy, and HIV/AIDS), while others are broad (including chronic pain or "any condition a physician deems appropriate"). The differences are significant — a condition that qualifies in one state may not qualify next door. Our Medical Programs by State guide can help you find your state's specific requirements, fees, and process.

Step 3: Get Your Medical Card

The process typically involves:

1. An evaluation by a licensed healthcare provider (in-person or via telehealth in many states)
2. The provider submitting a certification or recommendation to the state
3. Your completion of a state application and fee payment
4. Receipt of your medical cannabis card, usually within 1 to 4 weeks

Combined costs for the provider visit and state registration fee typically range from $100 to $300, with annual renewal required in most states. Some states offer expedited processing for an additional fee.

Step 4: Start Low, Go Slow

This is the most important dosing principle in cannabis medicine. Begin with the lowest available dose — typically 1 to 2.5 mg of THC — and increase gradually over days or weeks until you find the minimum effective dose that provides relief without unacceptable side effects. Resist the temptation to increase too quickly; many patients overshoot their optimal dose and experience unnecessary side effects. See our Dosing Fundamentals page for detailed guidance.

Step 5: Track Your Results

Keep a detailed journal recording the product used (name, cannabinoid content, terpene profile), dose, time of use, symptoms before and after, side effects, and overall quality of life. This data is invaluable for two reasons: it helps you identify what works and what does not, and it gives your healthcare provider concrete information to guide adjustments. See our Journaling & Tracking page for tools and templates.

Step 6: Follow Up with Your Provider

Medical cannabis is not a "set it and forget it" treatment. Regular check-ins with your healthcare provider allow for:

• Dose adjustments based on your response and journal data
• Monitoring for side effects, tolerance development, or dependency patterns
• Evaluation of whether cannabis is actually improving your outcomes compared to baseline
• Coordination with other treatments, including potential medication adjustments
• Reassessment of whether continued use is warranted

Medical vs. Recreational — Why the Distinction Matters

In states with both medical and recreational cannabis programs, you might wonder whether a medical card is worth the additional effort and cost. After all, if you can buy cannabis at a recreational dispensary, why go through the medical process? The answer comes down to several practical and legal advantages that can make a meaningful difference in your experience and outcomes.

• Goal-directed use: Medical use is focused on treating specific symptoms. This mindset shapes product selection, dosing, and how you evaluate success — and it tends to produce better health outcomes than unstructured use.
• Provider oversight: Medical patients who work with a knowledgeable healthcare provider benefit from professional guidance on dosing, drug interactions, and monitoring for adverse effects.
• Tax advantages: Most states tax medical cannabis at significantly lower rates than recreational products. In some states, this savings can amount to 15–25% or more per purchase.
• Legal protections: Medical patients in many states have additional legal protections, including some employment protections, higher possession limits, and in certain jurisdictions, housing protections that recreational users do not have.
• Access to medical-only products: Some states reserve higher-potency products, certain delivery methods, or specific formulations exclusively for medical patients.

However, the distinction is not always clear-cut. Some recreational users are effectively self-medicating for conditions they have not discussed with a healthcare provider. And some medical patients discover benefits beyond their qualifying condition. The key difference is the intentionality and structure that a medical approach provides.

The major downsides of medical programs: no insurance coverage (discussed below), the cost and effort of maintaining a medical card with annual renewals, and in some states, registration in a government database that some patients find concerning from a privacy standpoint.

The Cost of Medical Cannabis

One of the most important — and most frequently overlooked — factors in the decision to use medical cannabis is cost. Because cannabis remains a Schedule I substance under federal law, health insurance does not and cannot cover it. This means all costs come directly out of your pocket, which can be a significant consideration for patients on fixed incomes or those already managing high healthcare costs.

That said, the cost picture is not as bleak as it might first appear, especially when compared to the out-of-pocket costs of medications it may supplement or reduce the need for.

Typical Monthly Costs

• Average monthly spending: $100 to $300, depending on the condition being treated, product type, dosing needs, and local market prices.
• Medical card costs: $50 to $200 for the initial provider evaluation, plus $25 to $100 for the state registration fee. Most cards require annual renewal.
• Medical tax savings: In states with both medical and recreational sales, the medical card often pays for itself through reduced tax rates alone.

Comparison to Common Medications

For context, the out-of-pocket cost of medical cannabis is comparable to or less than many common medications it might supplement:

• Brand-name sleep medications: $100 to $400+ per month without insurance
• Brand-name anti-anxiety medications: $200 to $500+ per month without insurance
• Chronic pain management (including office visits, prescriptions, and procedures): often $300+ per month

However, the comparison is imperfect because most patients do have insurance covering those medications, making their effective cost lower. The real-world cost difference depends entirely on your insurance coverage for conventional treatments.

It is also worth considering indirect costs. Some patients report that effective symptom management with cannabis allows them to work more consistently, reduce other healthcare visits, or decrease spending on multiple over-the-counter products. These are harder to quantify but are part of the total cost picture for many patients.

Why Insurance Does Not Cover It

As long as cannabis remains federally classified as a Schedule I controlled substance — defined as having no accepted medical use and a high potential for abuse — insurance companies cannot cover it. Rescheduling to Schedule III (proposed but not yet finalized as of early 2026) could eventually change this, but coverage would not be immediate even after rescheduling.

Reducing Your Costs

While the cost of medical cannabis is real, there are ways to make it more manageable:

• Get a medical card for tax savings: In states with both programs, the reduced medical tax rate often saves patients $30 to $60+ per month, which can cover the cost of the card itself.
• Start with lower-cost delivery methods: Tinctures and capsules often provide more doses per dollar than flower or vaporizer cartridges, and their precise dosing helps avoid waste.
• Track your minimum effective dose: Using less product at the right dose is both cheaper and more effective than using more product at a higher dose. The "start low, go slow" approach saves money in addition to being safer.
• Ask about patient discounts: Many dispensaries offer discounts for veterans, seniors, low-income patients, and first-time buyers.

State Assistance Programs

Some states offer reduced medical card fees for low-income patients, veterans, Medicaid recipients, or those with disabilities. A few states waive the registration fee entirely for qualifying individuals. Check your state's program for financial assistance options through our Medical Programs by State guide.

Condition-Specific Deep Dives

This guide provides the big picture. For detailed, condition-specific information — including the specific research, recommended product profiles, dosing protocols, risks, and how to talk to your doctor about each condition — visit the relevant page below. Every condition page follows the same evidence-based structure and includes its own evidence rating.

The Bottom Line

Medical cannabis is a legitimate therapeutic option for certain conditions — backed by FDA-approved medications, thousands of published studies, and the experiences of millions of patients. It is also a field where hype frequently outpaces evidence, where marketing claims often exceed what the science supports, and where the lack of standardization means product quality and consistency vary widely.

The best approach is an informed one:

• Know where the evidence stands for your specific condition
• Work with a healthcare provider who can guide your decisions
• Start conservatively and track your results methodically
• Be honest with yourself about whether cannabis is actually improving your quality of life
• Revisit your decision periodically — what works at one stage of treatment may need adjustment

If you do all of that, you are already far ahead of most people navigating this space — and you are positioned to make a decision that is right for you, based on evidence rather than anecdote.

Further Reading

Key References

• National Academies of Sciences, Engineering, and Medicine (2017) — The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research
• Hsu et al. (2025), JAMA / UCLA Health — Comprehensive review of 2,500+ cannabis studies across all conditions
• Slawek et al. (2025), JAMA Internal Medicine — Medical cannabis and 22% opioid dose reduction among chronic pain patients
• Systematic review of cannabis for anxiety disorders (2025) — Psychiatry Research, including PTSD outcomes

Related Pages on TryCannabis.org

• Talking to Your Doctor — how to start the conversation
• Medical Programs by State — find your state's program and requirements
• Dosing Fundamentals — the "start low, go slow" approach in detail
• Journaling & Tracking — tools and templates for monitoring your progress
• What to Expect at a Dispensary — your first visit, demystified
• Who Should Not Use Cannabis — full contraindications and risk factors
• Drug Interactions — CYP450 interactions and medication safety
• Cannabis Use Disorder — understanding dependence risk
• Cannabis as Complement vs. Replacement — a balanced perspective
• The Evidence Gap — why cannabis research has been limited historically

External Resources

• Society of Cannabis Clinicians — find a provider trained in cannabis medicine
• Leaf411 — free consultations with cannabis-trained registered nurses
• Americans for Safe Access — patient advocacy, state program guides, and resources